The most common class of drugs used to treat Attention Deficit-Hyperactivity Disorder (ADHD) are the central nervous stimulants. These drugs stimulate specific areas of the central nervous system and aim to reverse the symptoms of ADHD. Medication for ADHD can be divided into stimulants such as methylphenidate, dexamphetamine, and lisdex amphetaminedimesylate, and non-stimulants such as atomoxetine. This review evaluates and critically discusses the pharmacotherapeutics of and neuronal systems involved in two drugs - methylphenidate and atomoxetine - prescribed for the treatment of ADHD in a paediatric behaviour clinic where children are assessed and treated for ADHD and co-morbid conditions. The presentation and prevalence of ADHD in children is also discussed.
|Number of pages||6|
|Journal||Journal of Healthcare|
|Publication status||Published - 08 Jun 2017|
Bibliographical note14/03/2021 - this article has been downloaded 2121 times
This demonstrates considerable impact and significant outreach since its publication in July 2017.
- Atomoxetine, Pharmacotherapeutics, ADHD